헤모글로빈 검사 시장 : 유형별, 기술별, 조작별, 용도별, 최종사용자별 - 세계 예측(2025-2030년)

The Hemoglobin Testing Market was valued at USD 5.70 billion in 2023, expected to reach USD 6.04 billion in 2024, and is projected to grow at a CAGR of 6.10%, to USD 8.63 billion by 2030.

Hemoglobin testing is an essential diagnostic procedure within the healthcare industry, primarily used to measure the amount of hemoglobin in blood, diagnose anemia, and monitor treatment efficacy in chronic conditions like diabetes. The necessity for hemoglobin testing stems from its role in providing critical health information, influencing patient management decisions across various medical specialties. Applications extend from routine health check-ups to specialized care settings, spanning areas like internal medicine, pediatrics, and hematology, with end-use predominant among hospitals, diagnostic laboratories, and homecare settings. Key growth factors impacting the hemoglobin testing market include an increasing prevalence of blood disorders, growing geriatric population, and advances in point-of-care testing technology. Additionally, trends such as the heightened focus on personalized medicine, and the rise in awareness and proactive healthcare practices are propelling market expansion. Opportunities can be seized in the development of non-invasive and rapid testing methods, integration with digital health platforms for enhanced data accessibility, and expansion into emerging markets where healthcare infrastructure is evolving rapidly. However, the market faces limitations like high costs associated with advanced diagnostic equipment and varying access to healthcare services globally, which can stymie growth potential. Stringent regulatory requirements may also pose as barriers to market entry for new players. Innovation can be driven by focusing on advancements in testing procedures that improve accuracy, reduce patient discomfort, and enhance user-friendly applications for non-specialist environments. Embracing AI and big data analytics to improve diagnostic insights and patient outcomes can also lead to significant improvements. Overall, the hemoglobin testing market demonstrates dynamic growth potential, yet it necessitates strategic navigation through regulatory landscapes and investment in technological innovations to maximize opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemoglobin Testing Market

The Hemoglobin Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of chronic diseases and need for regular hemoglobin level monitoring
  • Availability of improved and user-friendly point-of-care testing
  • Government initiatives promoting awareness about anemia testing
• Market Restraints
  • Complexity of certain testing methods and need for specialized skills
• Market Opportunities
  • Technological advancements in hemoglobin testing methods
  • Introduction of high-performing home hemoglobin testing kits and devices
• Market Challenges
  • Concerns associated with inaccuracy and false positives

Porter's Five Forces: A Strategic Tool for Navigating the Hemoglobin Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemoglobin Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemoglobin Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemoglobin Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemoglobin Testing Market

A detailed market share analysis in the Hemoglobin Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemoglobin Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemoglobin Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemoglobin Testing Market

A strategic analysis of the Hemoglobin Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemoglobin Testing Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, ACON Laboratories, Inc., AdvaCare Pharma, Arkray, Inc., ARUP Laboratories, Attikouris Enterprises Ltd., Avantor, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Boditech Med Inc., Clarity Diagnostics, LLC, Cliawaived, Inc., DiaSys Diagnostic Systems GmbH, EKF Diagnostics Holdings PLC by IBL PLC, F. Hoffmann-La Roche AG, HemoCue AB, Laboratory Corporation of America Holdings, Masimo Corp., Merck KGaA, Nova Biomedical, OrSense Ltd., PerkinElmer Inc., Qiagen N.V., Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sotera Health Company, Thermo Fisher Scientific Inc., Versiti, Inc., and VivaChek Biotech (Hangzhou) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Hemoglobin Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Blood Glucose Testing, Cyanmethemoglobin Method, and Hemoglobin Electrophoresis.
• Based on Technology, market is studied across Laboratory Testing and Point-of-Care Testing.
• Based on Operation, market is studied across Invasive Testing and Non-Invasive Testing. The Invasive Testing is further studied across Invasive Cuvette and Invasive Strip.
• Based on Application, market is studied across Anemia Diagnosis & Monitoring, Diabetes Diagnosis & Management, Sickle Cell Disease Screening, and Thalassemia Detection.
• Based on End-User, market is studied across Blood Bank, Diagnostic Laboratories, Homecare Settings, Hospitals & Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases and need for regular hemoglobin level monitoring
    • 5.1.1.2. Availability of improved and user-friendly point-of-care testing
    • 5.1.1.3. Government initiatives promoting awareness about anemia testing
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity of certain testing methods and need for specialized skills
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in hemoglobin testing methods
    • 5.1.3.2. Introduction of high-performing home hemoglobin testing kits and devices
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with inaccuracy and false positives
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Use of cyanmethemoglobin method as a standard and cost-effective technique for measuring total hemoglobin concentration
  • 5.2.2. Operation: Preference for non-invasive hemoglobin testing due to their convenience and ability to reduce discomfort associated with blood draws
  • 5.2.3. Application: Advanced hemoglobin testing solutions to determine the severity of anemia
  • 5.2.4. End-User: Availability of diverse range of hemoglobin testing to diagnose various hematological disorders
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hemoglobin Testing Market, by Type

• 6.1. Introduction
• 6.2. Blood Glucose Testing
• 6.3. Cyanmethemoglobin Method
• 6.4. Hemoglobin Electrophoresis

7. Hemoglobin Testing Market, by Technology

• 7.1. Introduction
• 7.2. Laboratory Testing
• 7.3. Point-of-Care Testing

8. Hemoglobin Testing Market, by Operation

• 8.1. Introduction
• 8.2. Invasive Testing
  • 8.2.1. Invasive Cuvette
  • 8.2.2. Invasive Strip
• 8.3. Non-Invasive Testing

9. Hemoglobin Testing Market, by Application

• 9.1. Introduction
• 9.2. Anemia Diagnosis & Monitoring
• 9.3. Diabetes Diagnosis & Management
• 9.4. Sickle Cell Disease Screening
• 9.5. Thalassemia Detection

10. Hemoglobin Testing Market, by End-User

• 10.1. Introduction
• 10.2. Blood Bank
• 10.3. Diagnostic Laboratories
• 10.4. Homecare Settings
• 10.5. Hospitals & Clinics
• 10.6. Research Institutes

11. Americas Hemoglobin Testing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Hemoglobin Testing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Hemoglobin Testing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Sanguina Receives US FDA Clearance for Haemoglobin Test Kit
  • 14.3.2. Mylab Introduces Indigenous Point-of-Care Sickle Cell Anaemia Test
  • 14.3.3. Hemex Health Awarded USD 3 Million Grant to Advance Commercialization of Gazelle Hb Variant Test for the U.S. market
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abcam PLC
• 2. ACON Laboratories, Inc.
• 3. AdvaCare Pharma
• 4. Arkray, Inc.
• 5. ARUP Laboratories
• 6. Attikouris Enterprises Ltd.
• 7. Avantor, Inc.
• 8. Becton, Dickinson and Company
• 9. Bio-Rad Laboratories, Inc.
• 10. Bio-Techne Corporation
• 11. Boditech Med Inc.
• 12. Clarity Diagnostics, LLC
• 13. Cliawaived, Inc.
• 14. DiaSys Diagnostic Systems GmbH
• 15. EKF Diagnostics Holdings PLC by IBL PLC
• 16. F. Hoffmann-La Roche AG
• 17. HemoCue AB
• 18. Laboratory Corporation of America Holdings
• 19. Masimo Corp.
• 20. Merck KGaA
• 21. Nova Biomedical
• 22. OrSense Ltd.
• 23. PerkinElmer Inc.
• 24. Qiagen N.V.
• 25. Quest Diagnostics Incorporated
• 26. Siemens Healthcare GmbH
• 27. Sotera Health Company
• 28. Thermo Fisher Scientific Inc.
• 29. Versiti, Inc.
• 30. VivaChek Biotech (Hangzhou) Co., Ltd.